ClinicalTrials.gg
CompletedNCT06670170Updated Sep 22, 2025

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

A Phase 1 interventional study of PF-07976016 Formulation A and PF-07976016 Formulation B in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to measure and compare the amount of study drug in your blood after a single dose of two formulations of study drug.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Participants
  • Healthy Subjects
  • Human Volunteers
  • Normal Volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and assessments.
  • Willing to provide consent and follow study requirements
  • Total body weight >110lbs (50kg)

Key Exclusion Criteria:

  • Any condition affecting drug absorption, laboratory values
  • , HepB \& HepC
  • Serious illness or hospitalization, or other condition, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Use of prescription or non-prescription drugs within a specified timeframe prior to the first dose of study intervention
  • positive urine drug test at screening/admission
  • History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening
  • Use of tobacco/nicotine containing products more than the equivalent of 5 cigarettes/day or 2 chews of tobacco/day
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Participants will receive a single dose of PF-07976016 in up to 3 study periods. In sequence 1, participants will receive formulation A followed by formulation B. There will be 7 days between each dose as a wash out period.

    Drug: PF-07976016 Formulation A · Drug: PF-07976016 Formulation B

  • Experimental
    Sequence 2

    Participants will receive single doses of PF-07976016 in up to 3 study periods. In sequence 2, participants will receive formulation B followed by formulation A. There will be 7 days between each dose as a wash out period.

    Drug: PF-07976016 Formulation A · Drug: PF-07976016 Formulation B

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve - infinity - AUCinf (as data permit, otherwise AUClast).

    Time frame: Day 1 Hour 0 (pre-dose) through 168 hours post dose in each period

Secondary outcomes

  1. Incidence of Treatment Emergent Adverse Events - TEAEs

    Time frame: From first dose (Day 1) up to 28-35 days after final dose; a total of approximately 51 days

07

Study locations

1 site
  • Pfizer Clinical Research Unit - New Haven
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Dec 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 1, 2024
StartActual
Nov 5, 2024
Primary completionActual
Dec 24, 2024
CompletionActual
Jan 17, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06670170
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Nov 5, 2024
Primary completion
Dec 24, 2024
Completion
Jan 17, 2025
Last update
Sep 22, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07976016

Start the discussion